Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
4,287 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06131840 | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 914 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT06666634 | Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy(NANOSCAN) | completed | N/A | 29 | The Netherlands Cancer InstituteOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07157605 | Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)(SPLENDID) | active not recruiting | — | 94 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 8 | Jul 22, 2026 | clinicaltrials |
| NCT07721181 | Radiotherapy Dose Escalation for Non-operative Management of Unresectable Locally Recurrent Rectal Cancer (STEP-UP)(STEP-UP) | recruiting | N/A | 30 | Heike M.U. PeulenOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT01933932 | Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC(SELECT-1) | active not recruiting | Phase 3 | 510 | AstraZenecaINDUSTRY | 26 | Jul 21, 2026 | clinicaltrials |
| NCT03445000 | ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer(ALERT-lung) | terminated | Phase 2 | 14 | ETOP IBCSG Partners FoundationNETWORK | 6 | Jul 21, 2026 | clinicaltrials |
| NCT04768972 | FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS) | active not recruiting | Phase 3 | 89 | Ionis Pharmaceuticals, Inc.INDUSTRY | 16 | Jul 21, 2026 | clinicaltrials |
| NCT05238922 | Study of INCB123667 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 | 291 | Incyte CorporationINDUSTRY | 8 | Jul 21, 2026 | clinicaltrials |
| NCT06472076 | A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) | active not recruiting | Phase 3 | 88 | GlaxoSmithKlineINDUSTRY | 21 | Jul 21, 2026 | clinicaltrials |
| NCT06996782 | A Platform Study in Non-Small Cell Lung Cancer (NSCLC)(ALTAIR) | recruiting | Phase 1 / Phase 2 | 152 | AstraZenecaINDUSTRY | 20 | Jul 21, 2026 | clinicaltrials |
| NCT03833154 | Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation(PACIFIC-4) | active not recruiting | Phase 3 | 724 | AstraZenecaINDUSTRY | 20 | Jul 20, 2026 | clinicaltrials |
| NCT04703192 | Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) | active not recruiting | Phase 2 | 155 | Daiichi SankyoINDUSTRY | 12 | Jul 20, 2026 | clinicaltrials |
| NCT06649695 | A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis | active not recruiting | Phase 2 | 30 | European Myeloma Network B.V.NETWORK | 6 | Jul 20, 2026 | clinicaltrials |
| NCT03732677 | Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC(NIAGARA) | active not recruiting | Phase 3 | 1,063 | AstraZenecaINDUSTRY | 22 | Jul 17, 2026 | clinicaltrials |
| NCT06413706 | A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | active not recruiting | Phase 2 | 45 | Eli Lilly and CompanyINDUSTRY | 10 | Jul 17, 2026 | clinicaltrials |
| NCT01523171 | Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib(JAKARTA2) | terminated | Phase 2 | 97 | Bristol-Myers SquibbINDUSTRY | 10 | Jul 16, 2026 | clinicaltrials |
| NCT03043872 | Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)(CASPIAN) | active not recruiting | Phase 3 | 987 | AstraZenecaINDUSTRY | 23 | Jul 16, 2026 | clinicaltrials |
| NCT03693170 | Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer(ANCHOR-CRC) | completed | Phase 2 | 95 | Pierre Fabre MedicamentINDUSTRY | 9 | Jul 16, 2026 | clinicaltrials |
| NCT04483739 | Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)(IsKia) | active not recruiting | Phase 3 | 302 | European Myeloma Network B.V.NETWORK | 8 | Jul 16, 2026 | clinicaltrials |
| NCT04564703 | Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients | active not recruiting | Phase 2 | 160 | Stichting European Myeloma NetworkNETWORK | 4 | Jul 16, 2026 | clinicaltrials |
| NCT05350722 | Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients(ABLATIVE-2) | recruiting | N/A | 100 | Amsterdam UMC, location VUmcOTHER | 2 | Jul 16, 2026 | clinicaltrials |
| NCT05727553 | Implementation of Online Adaptive Radiotherapy for Breast Cancer Patients on Ethos (BREAST-ART)(BREAST-ART) | completed | — | 50 | Amsterdam UMC, location VUmcOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06452485 | Postoperative Re-irradiaTion With and Without HYPERthermia, or Surgery Only: Toxicity, Quality of Life and Survival in Patients With Locoregional Recurrent Breast Cancer(RT-HYPE) | recruiting | — | 500 | Amsterdam UMC, location VUmcOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06640881 | Preoperative Partial Breast Reirradiation and Repeat Breast-conserving Surgery in Patients With Recurrent Breast Cancer: the REPEAT Trial(REPEAT) | recruiting | Phase 2 | 25 | Amsterdam UMC, location VUmcOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06084208 | Assessment of Diagnostic Yield Using a Robotic Navigational Bronchoscopy System With CBCT | completed | N/A | 132 | Intuitive SurgicalINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06237920 | Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab(TURANDORELA) | active not recruiting | Phase 2 | 90 | The Netherlands Cancer InstituteOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07258563 | The TASTY-steering Study(TASTY-steering) | recruiting | N/A | 201 | University Medical Center GroningenOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07258589 | The TASTY-training Study(TASTY-training) | recruiting | N/A | 90 | University Medical Center GroningenOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07377747 | Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma(ReLaPSe) | recruiting | — | 100 | Australia and New Zealand Sarcoma AssociationOTHER | 8 | Jul 15, 2026 | clinicaltrials |
| NCT02032823 | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer(OlympiA) | active not recruiting | Phase 3 | 1,837 | AstraZenecaINDUSTRY | 24 | Jul 14, 2026 | clinicaltrials |
| NCT02516241 | Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer | active not recruiting | Phase 3 | 1,126 | AstraZenecaINDUSTRY | 24 | Jul 14, 2026 | clinicaltrials |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.(MEDIOLA) | active not recruiting | Phase 1 / Phase 2 | 264 | AstraZenecaINDUSTRY | 7 | Jul 14, 2026 | clinicaltrials |
| NCT02864992 | Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) | active not recruiting | Phase 2 | 337 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 15 | Jul 14, 2026 | clinicaltrials |
| NCT04995523 | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC(ARTEMIDE-01) | active not recruiting | Phase 1 / Phase 2 | 212 | AstraZenecaINDUSTRY | 16 | Jul 14, 2026 | clinicaltrials |
| NCT07703033 | Multicenter Cardiac Decision Impact Study in People With Breast Cancer(CarDI) | recruiting | N/A | 1,000 | UMC UtrechtOTHER | 4 | Jul 14, 2026 | clinicaltrials |
| NCT04933695 | A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment(CodeBreaK201) | terminated | Phase 2 | 42 | AmgenINDUSTRY | 10 | Jul 13, 2026 | clinicaltrials |
| NCT05092009 | Lung Cancer Organoids and Patient Derived Tumor Xenografts(IPON-3) | active not recruiting | — | 600 | Maastricht Radiation OncologyOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05450692 | A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy(LATIFY) | active not recruiting | Phase 3 | 594 | AstraZenecaINDUSTRY | 23 | Jul 13, 2026 | clinicaltrials |
| NCT05700656 | Galunisertib Combined With Capecitabine in Advanced CRC With PM | active not recruiting | Phase 1 / Phase 2 | 31 | The Netherlands Cancer InstituteOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06652633 | Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies(Hesperia) | recruiting | Phase 3 | 546 | Lakefront Biotherapeutics NVINDUSTRY | 5 | Jul 13, 2026 | clinicaltrials |
| NCT06888817 | Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases(BRAINS) | recruiting | Phase 3 | 408 | The Netherlands Cancer InstituteOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT02813135 | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors(ESMART) | recruiting | Phase 1 / Phase 2 | 472 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 6 | Jul 10, 2026 | clinicaltrials |
| NCT03148418 | A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | active not recruiting | Phase 3 | 382 | Hoffmann-La RocheINDUSTRY | 32 | Jul 10, 2026 | clinicaltrials |
| NCT04482309 | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors(DPT02) | active not recruiting | Phase 2 | 477 | AstraZenecaINDUSTRY | 17 | Jul 10, 2026 | clinicaltrials |
| NCT05048797 | A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations | active not recruiting | Phase 3 | 454 | AstraZenecaINDUSTRY | 20 | Jul 10, 2026 | clinicaltrials |
| NCT05327894 | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia(Interfant-21) | recruiting | Phase 3 | 160 | Princess Maxima Center for Pediatric OncologyOTHER | 24 | Jul 10, 2026 | clinicaltrials |
| NCT05503264 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis(Cielo) | active not recruiting | Phase 3 | 122 | Hoffmann-La RocheINDUSTRY | 17 | Jul 10, 2026 | clinicaltrials |
| NCT06470763 | A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1) | completed | Phase 1 / Phase 2 | 63 | Anaveon AGINDUSTRY | 7 | Jul 10, 2026 | clinicaltrials |
| NCT00904241 | Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma | completed | — | 10,000 | Children's Oncology GroupNETWORK | 8 | Jul 9, 2026 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials